SCRI Development Innovations, LLC: Carcinoma, Non-Small-Cell Lung trials

The registry lists 16 Carcinoma, Non-Small-Cell Lung studies with SCRI Development Innovations, LLC as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 2 15No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerCompletedNCT01829113Phase 2Results posted
• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibCompletedNCT01487265Phase 2Results posted
• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLCCompletedNCT01042288Phase 2Results posted
• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerCompletedNCT01027598Phase 2Results posted
• Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCTerminatedNCT00960297Phase 2Results posted
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00906282Phase 2Results posted
• Trial of Poor Performance Status Patients (ToPPS)CompletedNCT00892710Phase 2Results posted
• Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerCompletedNCT00741988Phase 2Results posted
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCCompletedNCT00621049Phase 2Results posted
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibCompletedNCT00609804Phase 2Results posted
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2Results posted
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or LongerCompletedNCT01522833
• Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerCompletedNCT00193336Phase 2